Response patterns to bronchodilator and quantitative computed tomography in chronic obstructive pulmonary disease.

Department of Pulmonary and Critical Care Medicine, Asthma Center and Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Clinical Physiology and Functional Imaging (Impact Factor: 1.33). 01/2012; 32(1):12-8. DOI: 10.1111/j.1475-097X.2011.01046.x
Source: PubMed

ABSTRACT Patients with chronic obstructive pulmonary disease (COPD) show different spirometric response patterns to bronchodilator, such that some patients show improvement principally in expiratory flow (forced expiratory volume in 1 s; FEV(1)), whereas others respond by improvement of lung volume (forced vital capacity; FVC). The mechanisms of these different response patterns to bronchodilator remain unclear. We investigated the associations between bronchodilator responsiveness and quantitative computed tomography (CT) indices in patients with COPD.
Data on a total of 101 patients with stable COPD were retrospectively analysed. Volume and flow responses to bronchodilator were assessed by FVC and FEV(1) changes before and after inhalation of salbutamol (400 μg). Volumetric CT was performed to quantify emphysema, air trapping and large airway thickness. Emphysema was assessed by the volume fraction of the lung under -950 Hounsfield units (HU; V(950)) at full inspiration and air trapping by the ratio of mean lung density (MLD) at full expiration and inspiration. Airway wall thickness and wall area percentage (WA%; defined as wall area/[wall area + lumen area] × 100), were measured near the origin of right apical and left apico-posterior bronchus.
Among quantitative CT indices, the CT emphysema index (V(950 insp)) showed a significant negative correlation with postbronchodilator FEV(1) change (R = -0·213, P = 0·004), and the CT air-trapping index correlated positively with postbronchodilator FVC change(R = 0·286, P≤0·001). Multiple linear regression analysis showed that CT emphysema index had independent association with postbronchodilator FEV(1) change and CT air-trapping index with postbronchodilator FVC change.
The degrees of emphysema and air trapping may contribute to the different response patterns to bronchodilator in patients with COPD.

  • European Respiratory Journal 12/2013; 42(6):1441-5. DOI:10.1183/09031936.00168313 · 7.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract It is not known how airway structure is altered during real-life acute asthma exacerbations. The aim of this study was to examine changes in airway structure during acute asthma exacerbations and at convalescence by using lung-volume controlled high resolution computerised tomography (HRCT). Eight subjects with acute asthma exacerbation admitted to hospital were recruited. HRCT was performed within 72 hours of admission (n=8) and repeated after 8 weeks of convalescence (n=7). Individual airways were carefully matched on acute and convalescent CT data sets for comparisons of airway parameters. A novel methodology was employed for standardisation of lung volumes to permit valid comparisons of lung imaging. Measurements of bronchial cross sectional airway area (Aa) and bronchial luminal area (Ai) for each matched airway were obtained using a validated program. The airway wall thickness was analysed as wall area (WA) calculated as a percentage: WA% = WA/Aa x 100. Wilcoxon signed-rank testing was used to compare acute and convalescent asthma and Spearman's correlation to examine associations. Airway lumen (Ai) areas were similar in both acute and stable asthma phases (6.6±3.1mm(2) vs.7.2±3.8 mm(2) p=0.8). However, the airway wall was significantly thickened during acute asthma exacerbations compared to convalescence (62±4% vs. 55±7%; p=0.01). There was no correlation between airway structure dimensions and lung function measurements. This is the first study to demonstrate an increase in airway wall thickness during real-life acute asthma exacerbation. However, narrowing of the airway lumen area was variable and will require larger studies able to detect small differences. These results suggest that airway wall thickening linked to mucosal inflammation is likely to characterise acute asthma in vivo but that changes in the airway lumen accompanying bronchoconstriction may be more heterogeneous.
    Journal of Asthma 11/2013; DOI:10.3109/02770903.2013.860165 · 1.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Indacaterol is the first once-daily, long-acting β2-adrenergic agonist (LABA) approved for the treatment of chronic obstructive pulmonary disease (COPD). Indacaterol was developed using a combination of informed drug design and molecular chemistry to generate a β2-adrenergic agonist with a fast onset and long duration of action, enabling once-daily dosing with an acceptable safety profile. Early preclinical studies with indacaterol demonstrated these characteristics, and this promising molecule was taken into clinical development, originally for asthma treatment. Subsequent safety concerns over LABA monotherapy in patients with asthma redirected indacaterol's development to centre on COPD, where a good evidence base and guideline recommendations for bronchodilator monotherapy existed. Clinical development was initially complicated by different inhaler devices and differing doses of indacaterol. Using a phase III innovative adaptive-design clinical trial (INHANCE), indacaterol 150 and 300 μg once-daily doses were selected to be taken forward into the phase III INERGIZE programme. This programme delivered placebo-controlled and active-comparator data, including comparisons with formoterol, tiotropium and salmeterol/fluticasone, as well as the use of indacaterol in combination with tiotropium. Together, these studies provided a comprehensive assessment of the benefit-risk profile of indacaterol, allowing for regulatory submission. Indacaterol was first approved at once-daily doses of 150 and 300 μg in the European Union in 2009, followed by 150 µg in Japan (2011) and China (2012), and 75 μg in the United States (2011). To date, indacaterol is approved and marketed in more than 100 countries worldwide for once-daily maintenance treatment of COPD.
    Drugs 09/2014; 74(14). DOI:10.1007/s40265-014-0284-7 · 4.13 Impact Factor


Available from
May 29, 2014